Nanosystems as curative platforms for allergic disorder management

Fan, Peng-Sheng; Sun, Mengjie; Qin, Di; Yuan, Cong-Shan; Chen, Xiguang; Liu, Ya

doi:10.1039/d0tb02590a

Cited by 5 publications

(2 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…76 The treatment recommendations for conjunctivitis include pharmacological therapy targeting causes, such as antibiotics, 77 antivirals 78 and antifungals 79 and anti-allergy medications. 80 The common route of administration for ocular diseases is local administration on the ocular surface, of which, eye drops, ointments, and gels are the main dosage forms. However, because the conjunctival sac holds less fluid and affects eye blink behavior as well as orbicularis oculi muscle activity, the drug only stays on the ocular surface for a short time, which ultimately leads to a short time of the effective therapeutic concentration on the ocular surface.…”

Section: Conjunctivitismentioning

confidence: 99%

Ten Years of Knowledge of Nano-Carrier Based Drug Delivery Systems in Ophthalmology: Current Evidence, Challenges, and Future Prospective

Zhang¹,

Jiao²,

Niu³

et al. 2021

IJN

View full text Add to dashboard Cite

The complex drug delivery barrier in the eye reduces the bioavailability of many drugs, resulting in poor therapeutic effects. It is necessary to investigate new drugs through appropriate delivery routes and vehicles. Nanotechnology has utilized various nano-carriers to develop potential ocular drug delivery techniques that interact with the ocular mucosa, prolong the retention time of drugs in the eye, and increase permeability. Additionally, nano-carriers such as liposomes, nanoparticles, nano-suspensions, nano-micelles, and nano-emulsions have grown in popularity as an effective theranostic application to combat different microbial superbugs. In this review, we summarize the nano-carrier based drug delivery system developments over the last decade, particularly review the biology, methodology, approaches, and clinical applications of nano-carrier based drug delivery system in the field of ocular therapeutics. Furthermore, this review addresses upcoming challenges, and provides an outlook on potential future trends of nano-carrier-based drug delivery approaches in ophthalmology, and hopes to eventually provide successful applications for treating ocular diseases.

show abstract

Section: Conjunctivitismentioning

confidence: 99%

Ten Years of Knowledge of Nano-Carrier Based Drug Delivery Systems in Ophthalmology: Current Evidence, Challenges, and Future Prospective

Zhang¹,

Jiao²,

Niu³

et al. 2021

IJN

View full text Add to dashboard Cite

show abstract

“…Allergic diseases are immunoglobulin E (IgE)-mediated type I inflammatory disorders, including allergic rhinitis [1,2]. The major symptoms of allergic rhinitis are sneezing, nasal congestion, and lacrimation caused by complex allergen-driven mucosal inflammations, and the increased inflammatory mediators lead to sensory nerve activation, plasma leakage, and congestion [3,4]. The prevalence of these diseases in the USA ranges from 9 to 42%, and in the UK, it reaches 26% in adults [1,5].…”

Section: Introductionmentioning

confidence: 99%

Plant-Derived Lactobacillus paracasei IJH-SONE68 Improves Chronic Allergy Status: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

et al. 2021

View full text Add to dashboard Cite

We have recently demonstrated that the exopolysaccharides (EPSs) produced by a plant-derived lactic acid bacterium, Lactobacillus paracasei IJH-SONE68, prevent and ameliorate allergic reaction on contact in dermatitis model mice. In the present study, we conducted a clinical trial using a capsule containing spray-dried powder from pineapple juice broth fermented with the LAB strain as an experimental diet. The clinical trial was conducted as a double-blind and placebo-controlled randomized comparative study from May 2019 to July 2021. Males and females between the ages of 21 and 70 who experience chronic allergies participated in the study. Sixty subjects were instructed to orally take a capsule containing the IJH-SONE68 powder or placebo, every day for 12 weeks. After the clinical trial was over, the scores based on subjects’ self-assessment of allergic status were significantly improved in the intervention group, as compared with the placebo group. Some serum biochemicals associated with inflammation response were also significantly improved by intake of the experimental diet. In conclusion, the IJH-SONE68-derived EPS improves chronic allergy status in humans and is expected to decrease their inconvenience.

show abstract

Nanomaterials for antigen-specific immune tolerance therapy

Park

et al. 2022

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

Nanosystems as curative platforms for allergic disorder management

Abstract: Allergy, IgE-mediated inflammatory disorders including allergic rhinitis, asthma, and conjunctivitis, affects billions of people worldwide.

Cited by 5 publications

References 93 publications

Ten Years of Knowledge of Nano-Carrier Based Drug Delivery Systems in Ophthalmology: Current Evidence, Challenges, and Future Prospective

Ten Years of Knowledge of Nano-Carrier Based Drug Delivery Systems in Ophthalmology: Current Evidence, Challenges, and Future Prospective

Plant-Derived Lactobacillus paracasei IJH-SONE68 Improves Chronic Allergy Status: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Nanomaterials for antigen-specific immune tolerance therapy

Contact Info

Product

Resources

About